BioSpace News Archive

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that the Company has received positive scientific advice from the Committee for Medicinal Products for Human Use of the European Medicines Agency related to the pediatric label extension for NexoBrid.

Verrica Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has accepted the Company’s Investigational New Drug Application (“IND”) for LTX-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma.

BridgeBio Pharma, Inc. today announced that it has executed a definitive credit facility agreement with a syndicate of lenders for up to $750.0 million in financing.

Enveric Biosciences today announced that EV102, the Company’s cannabidiol (CBD) based product in development for topical prescription treatment of radiodermatitis, has demonstrated significant and meaningful reduction in dermatitis severity, skin redness, and duration in a preclinical rodent model.

Heron Therapeutics, Inc. today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion for the prevention of postoperative nausea and vomiting (PONV) in adults.

Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping calcitonin salmon injection, USP, multi-dose vials (2 mL) following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

Inflammatix announced today a contract extension of $12.1 million from the Biomedical Advanced Research and Development Authority (BARDA).

Nuvo Pharmaceuticals Inc. today announced it will host an investor presentation webcast on Thursday, December 2, 2021 at 2:00 p.m. ET (11:00 a.m. PT).

Oramed today announced the formation of a 50/50 joint venture between Genomma Lab and Oramed’s majority-owned subsidiary Oravax Medical Inc.

Biomind Labs Completes Development of a Thermosensitive Nasal Gel Pharmaceutical Dosage Form.